Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

Adagio Therapeutics, Inc. (ADGI)

Sector - Healthcare

Price chart

+95.88%
Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. They are developing their lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants. COVID-19 has caused the current global pandemic that remains a significant global health crisis and has resulted in millions of deaths and lasting health problems in many survivors. They believe that COVID-19 will become an endemic disease requiring a variety of effective, safe and convenient treatment and prevention options for years to come. They aim to address COVID-19 and future potential viral outbreaks by building a portfolio of antibodies with broadly neutralizing activity against multiple members of the coronavirus family or additional viruses with pandemic potential. Their portfolio of antibodies was discovered by Adimab, LLC, or Adimab, an industry leader in translating target hypotheses into therapeutically relevant antibodies with their proprietary platform, which has resulted in more than 385 antibody discovery programs, over 40 of which have advanced into clinical trials.
Industry
Biological Products (no Diagnostic Substances)
CEO CFO
Tillman U. Gerngross Jane Pritchett Henderson
Employees Founded
68 2020

Contacts

Address: 303 Wyman Street, Suite 300 Waltham, Ma 02451, Us

Telephone: (603) 252-2274

Web page: http://adagiotx.com

IPO information

First Trade Date 8/6/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 17.7
Shares Revised (MM) 18.2
Expected offer amount (MM) $300.9
Realized offer amount(MM) $309.4

Financial Data (last reporting year)

Market Cap (MM) $1836.3
Revenues (MM) $0
Net Income (Loss) (MM) $-104.0

Voting

What do you think will happen with the ADGI share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Morgan Stanley

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Morgan Stanley/ Jefferies/ Stifel/ Guggenheim Securities
CO-Managers

Sector: Healthcare

Tweets about $ADGI

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats